Cargando…

Prospective study of high-risk, BRCA1/2-mutation negative women: the ‘negative study’

BACKGROUND: We previously reported that women from high-risk families who tested negative for a BRCA1 or BRCA2 (BRCA1/2) mutation were four times more likely to develop breast cancer compared to women in the general population. Preventive measures and risk factors for breast cancer development in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotsopoulos, Joanne, Metcalfe, Kelly, Alston, Jill, Nikitina, Dina, Ginsburg, Ophira, Eisen, Andrea, Demsky, Rochelle, Akbari, Mohammad, Zbuk, Kevin, Narod, Steven A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973748/
https://www.ncbi.nlm.nih.gov/pubmed/24667084
http://dx.doi.org/10.1186/1471-2407-14-221
_version_ 1782479366146490368
author Kotsopoulos, Joanne
Metcalfe, Kelly
Alston, Jill
Nikitina, Dina
Ginsburg, Ophira
Eisen, Andrea
Demsky, Rochelle
Akbari, Mohammad
Zbuk, Kevin
Narod, Steven A
author_facet Kotsopoulos, Joanne
Metcalfe, Kelly
Alston, Jill
Nikitina, Dina
Ginsburg, Ophira
Eisen, Andrea
Demsky, Rochelle
Akbari, Mohammad
Zbuk, Kevin
Narod, Steven A
author_sort Kotsopoulos, Joanne
collection PubMed
description BACKGROUND: We previously reported that women from high-risk families who tested negative for a BRCA1 or BRCA2 (BRCA1/2) mutation were four times more likely to develop breast cancer compared to women in the general population. Preventive measures and risk factors for breast cancer development in these high-risk women have not been evaluated to the same extent as BRCA1/2 positive women. Further, there is virtually no scientific evidence about best practices in their management and care. The proposed study will examine a role of genetic and non-genetic factors and develop the systems and parameters for the monitoring and surveillance necessary to help establish guidelines for the care of this high-risk population. METHODS/DESIGN: To achieve our goals, we will assemble and follow a Canadian cohort of 1,000 cancer-free women with a strong family history breast cancer (defined as two or more relatives affected by breast cancer under the age of 50, or three or more relatives diagnosed with breast cancer at any age from one side of the family and with no BRCA1/2 mutation in the family). All eligible participants will be mailed a study package including invitation to participate, consent form, a research questionnaire to collect data regarding family history, reproductive and lifestyle factors, as well as screening and surgery. Usual dietary intake will be assessed by a diet history questionnaire. Biological samples including toenail clippings, urine and blood samples will be collected. These women will be followed every two years by questionnaire to update exposure information, screening practices, surgical and chemoprevention, and disease development. DISCUSSION: Findings from this study will serve to help establish clinical guidelines for the implementation of prevention, counseling, and treatment practices for women who face an elevated risk of breast cancer due to family history, but who do not carry a BRCA1/2 mutation.
format Online
Article
Text
id pubmed-3973748
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39737482014-04-04 Prospective study of high-risk, BRCA1/2-mutation negative women: the ‘negative study’ Kotsopoulos, Joanne Metcalfe, Kelly Alston, Jill Nikitina, Dina Ginsburg, Ophira Eisen, Andrea Demsky, Rochelle Akbari, Mohammad Zbuk, Kevin Narod, Steven A BMC Cancer Study Protocol BACKGROUND: We previously reported that women from high-risk families who tested negative for a BRCA1 or BRCA2 (BRCA1/2) mutation were four times more likely to develop breast cancer compared to women in the general population. Preventive measures and risk factors for breast cancer development in these high-risk women have not been evaluated to the same extent as BRCA1/2 positive women. Further, there is virtually no scientific evidence about best practices in their management and care. The proposed study will examine a role of genetic and non-genetic factors and develop the systems and parameters for the monitoring and surveillance necessary to help establish guidelines for the care of this high-risk population. METHODS/DESIGN: To achieve our goals, we will assemble and follow a Canadian cohort of 1,000 cancer-free women with a strong family history breast cancer (defined as two or more relatives affected by breast cancer under the age of 50, or three or more relatives diagnosed with breast cancer at any age from one side of the family and with no BRCA1/2 mutation in the family). All eligible participants will be mailed a study package including invitation to participate, consent form, a research questionnaire to collect data regarding family history, reproductive and lifestyle factors, as well as screening and surgery. Usual dietary intake will be assessed by a diet history questionnaire. Biological samples including toenail clippings, urine and blood samples will be collected. These women will be followed every two years by questionnaire to update exposure information, screening practices, surgical and chemoprevention, and disease development. DISCUSSION: Findings from this study will serve to help establish clinical guidelines for the implementation of prevention, counseling, and treatment practices for women who face an elevated risk of breast cancer due to family history, but who do not carry a BRCA1/2 mutation. BioMed Central 2014-03-25 /pmc/articles/PMC3973748/ /pubmed/24667084 http://dx.doi.org/10.1186/1471-2407-14-221 Text en Copyright © 2014 Kotsopoulos et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Kotsopoulos, Joanne
Metcalfe, Kelly
Alston, Jill
Nikitina, Dina
Ginsburg, Ophira
Eisen, Andrea
Demsky, Rochelle
Akbari, Mohammad
Zbuk, Kevin
Narod, Steven A
Prospective study of high-risk, BRCA1/2-mutation negative women: the ‘negative study’
title Prospective study of high-risk, BRCA1/2-mutation negative women: the ‘negative study’
title_full Prospective study of high-risk, BRCA1/2-mutation negative women: the ‘negative study’
title_fullStr Prospective study of high-risk, BRCA1/2-mutation negative women: the ‘negative study’
title_full_unstemmed Prospective study of high-risk, BRCA1/2-mutation negative women: the ‘negative study’
title_short Prospective study of high-risk, BRCA1/2-mutation negative women: the ‘negative study’
title_sort prospective study of high-risk, brca1/2-mutation negative women: the ‘negative study’
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973748/
https://www.ncbi.nlm.nih.gov/pubmed/24667084
http://dx.doi.org/10.1186/1471-2407-14-221
work_keys_str_mv AT kotsopoulosjoanne prospectivestudyofhighriskbrca12mutationnegativewomenthenegativestudy
AT metcalfekelly prospectivestudyofhighriskbrca12mutationnegativewomenthenegativestudy
AT alstonjill prospectivestudyofhighriskbrca12mutationnegativewomenthenegativestudy
AT nikitinadina prospectivestudyofhighriskbrca12mutationnegativewomenthenegativestudy
AT ginsburgophira prospectivestudyofhighriskbrca12mutationnegativewomenthenegativestudy
AT eisenandrea prospectivestudyofhighriskbrca12mutationnegativewomenthenegativestudy
AT demskyrochelle prospectivestudyofhighriskbrca12mutationnegativewomenthenegativestudy
AT akbarimohammad prospectivestudyofhighriskbrca12mutationnegativewomenthenegativestudy
AT zbukkevin prospectivestudyofhighriskbrca12mutationnegativewomenthenegativestudy
AT narodstevena prospectivestudyofhighriskbrca12mutationnegativewomenthenegativestudy